You are here: Home / People / Dr. Lisa Johanna von Kleist

"Basic research wants to know the world, applied research wants to shape the world."

Dr. Lisa Johanna von Kleist
+49 (0) 30 310078-5824

Focal areas of work

  • Active ingredient research
  • Biotechnology
  • Pharmaceutical industry
  • Cell Biology
  • Molecular Pharmacology
  • Technology Transfer

Curriculum Vitae

Dr. Lisa von Kleist studied chemistry at the University of Gothenburg in Sweden, majoring in molecular biology, biochemistry and pharmacology. She received her PhD in biochemistry from the Free University of Berlin with a focus on the development of novel drugs against, among other things, virus uptake. Subsequently, she spent several years conducting studies, analyses and research in the fields of biotechnology and life sciences for public and private clients. Her main focus was on drug discovery and technology transfer in the context of academic research and pharmaceutical companies as employers and customers. Since 2019, she has been working for VDI/VDE Innovation + Technik GmbH as a research associate, among other things on behalf of the Global Health Department in the Federal Ministry of Education and Research.


  • Pervaiz S, Kopp A, von Kleist L, Stauber T. Absolute protein amounts and relative abundance of volume-regulated anion channel (VRAC) LRRC8 subunits in cells and tissues revealed by quantitative immunoblotting. International Journal of Molecular Sciences, 20(23), 5879, 2019
  • Khundadze M, Ribaudo F, Hussain A, Rosentreter J, Nietzsche S, Thelen M, Winter D, Hoffmann B, Afzal MA, Hermann T, de Heus C, Piskor E-M, Kosan C, Franzka P, von Kleist L, Stauber T, Klumperman J, Damme M, Proikas-Cezanne T, Hübner CA. A mouse model for SPG48 reveals a block of autophagic flux upon disruption of adaptor protein complex five. Neurobiology of Disease, 127, 419-431, 2019
  • von Kleist L, Ariunbat K, Braren I, Stauber T, Storch S, Danyukova T. A newly generated neuronal cell model of CLN7 disease reveals aberrant lysosome motility and impaired cell survival. Molecular Genetics and Metabolism, 126, 196-205, 2018
  • König B, von Kleist L, Stauber T. Measurement of lysosomal ion homeostasis by fluorescence microscopy (book chapter) in Fluorescence Imaging and Biological Quantification, Taylor & Francis, 2017
  • Robertson MJ, Horatscheck A, Sauer S, von Kleist L, Baker JR, Stahlschmidt W, Nazaré M, Whiting A, Chau N, Robinson PJ, Haucke V, McCluskey A. 5-Aryl-2-(naphtha-1-yl)sulfonamido-thiazol-4(5H)-ones as clathrin inhibitors. Organic and Biomolecular Chemistry, 14(47), 11266-11278, 2016
  •  von Kleist L, Michaelis S, Bartho K, Graebner O, Schlief M, Dreger M, Schrey AK, Sefkow M, Kroll F, Koester H, Luo Y. Identification of potential off-target toxicity liabilities of catechol-O-methyltransferase inhibitors by differential competition capture compound mass spectrometry. Journal of Medicinal Chemistry, 59(10), 4664–4675, 2016
  •  Luo L, Xue J, Kwan A, Gamsjaeger R, Wielens J, von Kleist L, Cubeddu L, Guo Z, Stow JL, Parker MW, Mackay JP, Robinson PJ. The binding of syndapin SH3 domain to dynamin proline-rich domain involves short and long distance elements. Journal of Biological Chemistry, 291(18), 9411–9424, 2016
  •  Diezmann F, von Kleist L, Haucke V, Seitz O.  Probing heterobivalent binding to the endocytic AP-2 adaptor complex by DNA-based spatial screening. Organic and Biomolecular Chemistry, 13(29), 8008-8015, 2015
  •  Daniel JA, Chau N, Abdel-Hamid MK, Hu L, von Kleist L, Whiting A, Krishnan S, Maamary P, Joseph SR, Simpson F, Haucke V, McCluskey A, Robinson PJ. Phenothiazine-derived antipsychotic drugs inhibit dynamin and clathrin-mediated endocytosis. Traffic, 16(6), 635-654, 2015
  •  Robertson MJ, Deane FM, Stahlschmidt W, von Kleist L, Haucke V, Robinson PJ, McCluskey A. Synthesis of the pitstop family of clathrin inhibitors. Nature Protocols, 9(7), 1592-1606, 2014
  •  MacGregor KA, Robertson MJ, Young KA, von Kleist L, Stahlschmidt W, Whiting A, Chau N, Robinson PJ, Haucke V, McCluskey A. Development of 1,8-naphthalimides as clathrin inhibitors. Journal of Medicinal Chemistry, 57(1), 131–143, 2014
  •  Leclercq O*, Bartho K*, Duelsner E*, von Kleist L*, Gherardini PF, Palmeri A, Helmer-Citterich M, Baumgart S, Späth GF. Enrichment of Leishmania donovani ATP-binding proteins using a staurosporine capture compound. Journal of Proteomics, 86, 97–104, 2013, *equal contribution
  •  McCluskey A, Daniel JA, Hadzic G, Chau N, Clayton EL, Mariana A, Whiting A, Gorgani NN, Lloyd J, Quan A, Moshkanbaryans L, Krishnan S, Perera S, Chircop M, von Kleist L, McGeachie AB, Howes MT, Parton RG, Campbell M, Sakoff JA, Wang X, Sun JY, Robertson MJ, Deane FM, Nguyen TH, Meunier FA, Cousin MA, Robinson PJ. Building a better dynasore: the dyngo compounds potently inhibit dynamin and endocytosis. Traffic, 14(12), 1272–1289, 2013
  •  Robertson MJ, Hadzic G, Ambrus J, Pomè DY, Hyde E, Whiting A, Mariana A, von Kleist L, Chau N, Haucke V, Robinson PJ, McCluskey A. The rhodadyns, a new class of small molecule inhibitors of dynamin GTPase activity. ACS Medicinal Chemistry Letters, 3(5), 352–356, 2012
  •  von Kleist L, Haucke V. At the crossroads of chemistry and cell biology: inhibiting membrane traffic by small molecules. Traffic, 13(4), 495–504, 2012
  •  von Kleist L, Stahlschmidt W, Bulut H, Gromova K, Puchkov D, Robertson MJ, MacGregor KA, Tomilin N, Pechstein A, Chau N, Chircop M, Sakoff J, von Kries JP, Saenger W, Kräusslich HG, Shupliakov O, Robinson PJ, McCluskey A, Haucke V. Role of the clathrin terminal domain in regulating coated pit dynamics revealed by small molecule inhibition. Cell, 146(3), 471–484, 2011

Share this page: